Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice

BACKGROUND: Metformin, an FDA-approved drug for the treatment of Type II diabetes, has emerged as a promising anti-cancer agent. Other biguanide analogs, including buformin and phenformin, are suggested to have similar properties. Although buformin was shown to reduce mammary tumor burden in carcino...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Exp Clin Cancer Res
Main Authors: Parris, Amanda B., Zhao, Qingxia, Howard, Erin W., Zhao, Ming, Ma, Zhikun, Yang, Xiaohe
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2017
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5307817/
https://ncbi.nlm.nih.gov/pubmed/28193239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-017-0498-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares